Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $148.9 million.

  • Artiva Biotherapeutics' Liabilities and Shareholders Equity fell 3401.39% to $148.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $719.1 million, marking a year-over-year increase of 7684.66%. This contributed to the annual value of $209.6 million for FY2024, which is 9938.45% up from last year.
  • Per Artiva Biotherapeutics' latest filing, its Liabilities and Shareholders Equity stood at $148.9 million for Q3 2025, which was down 3401.39% from $169.4 million recorded in Q2 2025.
  • Over the past 5 years, Artiva Biotherapeutics' Liabilities and Shareholders Equity peaked at $225.6 million during Q3 2024, and registered a low of $75.9 million during Q2 2024.
  • Its 3-year average for Liabilities and Shareholders Equity is $160.8 million, with a median of $169.4 million in 2025.
  • The largest annual percentage gain for Artiva Biotherapeutics' Liabilities and Shareholders Equity in the last 5 years was 12314.13% (2025), contrasted with its biggest fall of 3401.39% (2025).
  • Over the past 3 years, Artiva Biotherapeutics' Liabilities and Shareholders Equity (Quarter) stood at $105.1 million in 2023, then skyrocketed by 99.38% to $209.6 million in 2024, then dropped by 28.97% to $148.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $148.9 million in Q3 2025, compared to $169.4 million in Q2 2025 and $191.3 million in Q1 2025.